KZR-616 offers a novel approach to harmonizing the immune system via selective immunoproteasome inhibition. Playing a critical role in the body's immune system, the immunoproteasome is abundantly expressed in immune cells and acts as a master regulator of multiple cellular functions. By selectively inhibiting the immunoproteasome, KZR-616 has the potential to affect multiple drivers of immune-mediated diseases.
With its broad immunomodulatory capabilities, KZR-616 has broad therapeutic potential and is distinctly different from other drugs available to those living with autoimmune diseases. KZR-616 is active in a number of animal models of autoimmune diseases and supported by compelling early clinical data, KZR-616 offers a “pipeline in a drug” with the potential to disrupt the treatment paradigm in a wide array of immune-mediated and autoimmune diseases.
The MISSION Phase 1b trial, which is evaluating the safety, tolerability and early efficacy signals in patients with lupus with and without nephritis, has completed enrollment. Data gathered to date support the development of KZR-616 as a chronic therapy for a wide range of severe, chronic autoimmune diseases and immune-mediated disorders. Phase 2 clinical trials are currently underway in lupus nephritis and dermatomyositis/polymyositis.